US/UK/Canada

Share

Contacts

  • Immunovia AB
    Medicon Village Scheelevägen 8 SE-223 63 Lund
    +46 46 275 60 00
    http://www.immunovia.com
    • Pick a time period -
    Tags ( Active)

    Immunovia announces financial targets

    LUND, Sweden - The Board of Directors of Immunovia AB (publ) (“Immunovia” or the “Company”) has today adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018. The financial targets show that the Company’s goal is to reach SEK 250-300 million in turnover in 2021 based on “self-pay”-sales and a turnover of SEK 800-1,000 million in 2023 including self-pay and reimbursements in Europe and the US.Immunovia performs clinical validation studies for the commercialization of IMMray™ PanCan-d, which may be the first blood-based test

    Immunovia: Insiders transfer subscription rights free of charge

    LUND, Sweden ― Within the framework of the ongoing rights issue at Immunovia AB (publ) ("the company ") Carl Borrebaeck and Christer Wingren, Chairman of the Board and Chief Technical Officer respectively at the company, have, on request from professional investors and in consultation with the company's financial advisor Vator Securities, transferred all subscription rights received in the rights issue to named investors.The purpose of the transfer is to further strengthen the company's shareholder base with long-term professional investors. The transfers have been made free of charge and

    Immunovia publishes prospectus regarding preferential rights issue

    NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia publishes prospectus regarding preferential rights issue Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”). Publication of prospectusImmunovia’s prospectus, prepared in connection with

    Immunovia intends to launch a directed and preferential right issue

    NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia intends to launch a directed and preferential right issue SummaryImmunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares. Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK

    Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer

    The best chance to influence the survival of non-hereditary pancreatic cancer patients is to focus on early detection of cases in people aged over 50 who receive their first diagnosis of diabetes. There is now clear unanimity on this, and both public authorities and health institutes focused on the link between diabetes and pancreatic cancer are initiating research programmes on a large scale across several countries in order to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group.To achieve clear results that

    Immunovia Half-year report 2016

    “Immunovia reached several important milestones in the first six months of 2016. Good results were obtained in the American pancreas study that was carried out in collabo­ration with Knight Cancer Institute. Presentations made at the key global conferences concerning pancreatic cancer were very well received. A specially strong Scientific Advisory Board has been recruited, and involvement from the patient organization has increased. Furthermore, several significant agreements were signed with important cancer centres. The market introduction of IMMray™ PanCan –d, Immunovia’s diagnosis

    Immunovia invitation to a teleconference on 24 August 2016

    Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same dayImmunovia invites you to a teleconference in connection with the publishing of the first half-year’s results for 2016. The conference call, which is expected to last for a maximum one hour, will be held in Swedish. After a presentation of the company by CEO Mats Grahn, you will have the opportunity to ask questions. Please dial in a few minutes before

    Immunovia announces intention to apply for listing on Nasdaq Stockholm's Main Market

    The Board of Immunovia AB (publ) ("Immunovia" or the "Company") today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm's Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker."Our shareholder base has gradually become broader since our listing on the Nasdaq First North on December 1, 2015. With the listing of Immunovia’s shares on Nasdaq Stockholm Main Market we are now taking the next step to get access to the international capital market and making it easier for

    Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board

    Extensive expertise in clinical tumor management and tumor biomarkers, will help accelerate pancreatic cancer diagnostic programLUND, Sweden ― Immunovia announced today that Prof. Diane Simeone, Greenfield Endowed Professor of Surgery and Physiology at the University of Michigan Medical Center and the Director of the Pancreatic Cancer Center and a leading authority on the management of solid and cystic pancreatic tumors, has joined the company’s Scientific Advisory Board. This latest appointment is in line with Immunovia´s strategy to deliver the first validated test for early diagnosis of

    World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board

    LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology and Diagnostics at the University and Hospital Trust of Verona in Italy.Prof. Scarpa received his MD from the University of Padua and his PhD in Human Oncology and Molecular Pathology from the University of Verona.

    Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board

    LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF.Professor Tempero is a professor of medicine in Hematology and Oncology and a pioneer in applying radioactively tagged antibodies for cancer therapy and is leading national US research projects for gastrointestinal

    Double pancreatic cancer survival by 2020

    World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancerLUND, Sweden - The days between 10 to 15 of May, 2016 were dedicated to the deadliest form of cancer, pancreatic cancer, by two major events that

    96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort

    Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer(LUND, Sweden) ― Immunovia announced today that they have completed a second retrospective clinical validation study showing 96% accuracy for early detection of 90 early stage I & II North American pancreatic cancer patients, which perfectly matches the previously reported Scandinavian study results (link to press release ). To confirm the performance of the test in a U.S.

    Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

    Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer.LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Dr. Marco Del Chiaro, a world recognized expert surgeon in pancreatic diseases, transplantation and robotic surgery has been appointed to the company’s Scientific Advisory Board. Marco Del Chiaro, MD, PhD, FACS is presently an associate professor of surgery and Head of Pancreatic Surgery Unit at

    Immunovia partners with leading healthcare consultingservices firm

    Immunovia partners with leading healthcare consulting services firm to support market access of pancreatic cancer test in Germany*Immunovia announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray™ PanCan-d in GermanyLUND, Sweden ― Immunovia, a life science company focused on developing blood-based diagnostic tests for cancer and autoimmune diseases, announced today that they enter into an advisory collaboration agreement with Ehlers, Ehlers and Partner which is Germany’s choice for life science and healthcare legal and reimbursement

    Immunovia launches Swedish website

    LUND, Sweden ― Immunovia AB today introduces its website in Swedish as part of the efforts to grow its presence in the Scandinavian home markets. The company launched its global website one year ago and online reports show high total number of visitors from all around the world. However, since December last year, when the company was listed on Nasdaq First North in Stockholm, a lot of additional traffic to the website comes from the Swedish audience. “As we start to grow globally and expand into strategic markets, enabling local customers and investors to explore and learn about our

    Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

    Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLELUND, Sweden ― Immunovia AB announced today that the company has entered into an agreement with a large multinational life science company to run joint studies aimed at expanding the applications area of IMMray™, to autoimmune diseases. The market for SLE diagnosis is large as it is estimated that 5 million people suffer from SLE worldwide, with 100,000 new cases reported every year. As one of the most difficult to diagnose and monitor

    Immunovia Year-end report 2015

    "In 2015 Immunovia took important steps toward commercialisation of the world’s first blood-based test for cancer diagnosis, IMMray™ PanCan –d. We were able to prove, with 96% accuracy, that our test can diagnose the early stages of pancreatic cancer. In the second half of the year we signed a comprehensive agreement with Knight Cancer Institute at Oregon Health & Science University, USA, which during the year received a donation of USD 1 billion to achieve radical changes in cancer care globally through a focus on early diagnosis. Cooperation with Knight Cancer Institute will be decisive

    Immunovia, OHSU collaborating on early detection test for pancreatic cancer

    LUND, Sweden, and PORTLAND, Oregon ― Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of about 6 percent. It is the second most common cause of

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media